BridgeBio Pharma, Inc. reports results for the quarter ended June 30 - Earnings Summary

BridgeBio Pharma

10/08/2026 22:01

BridgeBio Pharma, Inc. BBIO.OQ reported a quarterly adjusted loss of 78 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -95 cents.  The mean expectation of nineteen analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -88 cents to -37 cents per share.
Revenue rose 120.4% to $243.68 million from a year ago; analysts expected $218.74 million. 
BridgeBio Pharma, Inc.'s reported EPS for the quarter was a loss of 78 cents​.
The company reported a quarterly loss of $152.22 million.
BridgeBio Pharma, Inc. shares had risen by 13.4% this quarter and gained 10.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2.8% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for BridgeBio Pharma, Inc. is $101.50, about 16.8% above its last closing price of $84.48
This summary was machine generated from LSEG data August 10 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.58
-0.78
Missed
Mar. 31 2026 
-0.68
-0.84
Missed
Dec. 31 2025 
-0.74
-1.00
Missed
Sep. 30 2025 
-0.89
-0.95
Missed